scholarly journals Systemic Expression of Heme Oxygenase-1 Ameliorates Type 1 Diabetes in NOD Mice

Diabetes ◽  
2007 ◽  
Vol 56 (5) ◽  
pp. 1240-1247 ◽  
Author(s):  
C.-M. Hu ◽  
H.-H. Lin ◽  
M.-T. Chiang ◽  
P.-F. Chang ◽  
L.-Y. Chau
2019 ◽  
Vol 20 (7) ◽  
pp. 1676 ◽  
Author(s):  
Julien Pogu ◽  
Sotiria Tzima ◽  
Georges Kollias ◽  
Ignacio Anegon ◽  
Philippe Blancou ◽  
...  

Antigen-presenting cells (APCs) including dendritic cells (DCs) play a critical role in the development of autoimmune diseases by presenting self-antigen to T-cells. Different signals modulate the ability of APCs to activate or tolerize autoreactive T-cells. Since the expression of heme oxygenase-1 (HO-1) by APCs has been associated with the tolerization of autoreactive T-cells, we hypothesized that HO-1 expression might be altered in APCs from autoimmune-prone non-obese diabetic (NOD) mice. We found that, compared to control mice, NOD mice exhibited a lower percentage of HO-1-expressing cells among the splenic DCs, suggesting an impairment of their tolerogenic functions. To investigate whether restored expression of HO-1 in APCs could alter the development of diabetes in NOD mice, we generated a transgenic mouse strain in which HO-1 expression can be specifically induced in DCs using a tetracycline-controlled transcriptional activation system. Mice in which HO-1 expression was induced in DCs exhibited a lower Type 1 Diabetes (T1D) incidence and a reduced insulitis compared to non-induced mice. Upregulation of HO-1 in DCs also prevented further increase of glycemia in recently diabetic NOD mice. Altogether, our data demonstrated the potential of induction of HO-1 expression in DCs as a preventative treatment, and potential as a curative approach for T1D.


2008 ◽  
Vol 35 (7) ◽  
pp. 820-826 ◽  
Author(s):  
Wei-Li Shen ◽  
Mei-Fang Zhong ◽  
Wen-Long Ding ◽  
Jian Wang ◽  
Lin Zheng ◽  
...  

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1190-P
Author(s):  
NOÉMIE CAILLOT ◽  
FABIEN COLAONE ◽  
ROMAIN BERTRAND ◽  
JENNIFER DA SILVA ◽  
SAMIR HAMDI ◽  
...  
Keyword(s):  
Nod Mice ◽  

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1817-P
Author(s):  
FRANÇOIS A. LEBLOND ◽  
KATHY HINCE ◽  
FRANÇOIS SARRA-BOURNET ◽  
WILLIAM GAGNON ◽  
MIKAËL TREMBLAY ◽  
...  
Keyword(s):  

2019 ◽  
Author(s):  
Fujian Qin ◽  
Yanfeng Zhang ◽  
Kaiying Li ◽  
Huashan Gao ◽  
Qian Zhao ◽  
...  

2014 ◽  
Vol 20 (9) ◽  
pp. 1328-1337 ◽  
Author(s):  
Shuchita Tiwari ◽  
Joseph Ndisang

Author(s):  
Tiantian Yue ◽  
Fei Sun ◽  
Faxi Wang ◽  
Chunliang Yang ◽  
Jiahui Luo ◽  
...  

AbstractThe methyl-CpG-binding domain 2 (MBD2) interprets DNA methylome-encoded information through binding to the methylated CpG DNA, by which it regulates target gene expression at the transcriptional level. Although derailed DNA methylation has long been recognized to trigger or promote autoimmune responses in type 1 diabetes (T1D), the exact role of MBD2 in T1D pathogenesis, however, remains poorly defined. Herein, we generated an Mbd2 knockout model in the NOD background and found that Mbd2 deficiency exacerbated the development of spontaneous T1D in NOD mice. Adoptive transfer of Mbd2−/− CD4 T cells into NOD.scid mice further confirmed the observation. Mechanistically, Th1 stimulation rendered the Stat1 promoter to undergo a DNA methylation turnover featured by the changes of DNA methylation levels or patterns along with the induction of MBD2 expression, which then bound to the methylated CpG DNA within the Stat1 promoter, by which MBD2 maintains the homeostasis of Th1 program to prevent autoimmunity. As a result, ectopic MBD2 expression alleviated CD4 T cell diabetogenicity following their adoptive transfer into NOD.scid mice. Collectively, our data suggest that MBD2 could be a viable target to develop epigenetic-based therapeutics against T1D in clinical settings.


Sign in / Sign up

Export Citation Format

Share Document